leading semaglutide law office digestive blockage legal team in louisiana glp-1 bowel obstruction Popular GLP-1 drugs may lead to increased risk of gastrointestinal problems, study found semaglutide digestive blockage – FDA, Novo Nordisk Warn of

The 1.7mg dose was not part of the original STEP trial protocol for semaglutide 2.4mg (which used 0.25, 0.5, 1.0, 1.7, then 2.4), but it serves as a crucial intermediate step that reduces the jump between 1.0mg and 2.4mg

At present, the mechanism of the apoptosis theory is widely recognized as regards the pathogenesis of MC

Compounded versus brand-name GLP-1: does the source affect reactions

Coverage policies vary widely: a KFF 2025 employer survey found 43% of firms with 5,000+ workers now cover GLP-1 weight-loss drugs (up from 28% in 2024) ( [6] ), yet many patient advocacy reports and journalists note patients cutting doses or resorting to unapproved sources due to cost ( [4] ) ( [7] )